<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914536</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-POM-2013-46</org_study_id>
    <nct_id>NCT01914536</nct_id>
  </id_info>
  <brief_title>A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI</brief_title>
  <acronym>POMPE 2013</acronym>
  <official_title>A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is an observational prospective study in which patients affected by an adult&#xD;
      onset Pompe disease will be followed-up during three years using different clinical,&#xD;
      analytical and radiological tests in order to know which is the natural history of the&#xD;
      disease and which is the impact that treatment with recombinant enzyme has in the progression&#xD;
      of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study aim:&#xD;
&#xD;
      The principal objective of the study is to find biomarkers that quantify the natural&#xD;
      progression of the disease and to know if they are useful to determine the improvement or&#xD;
      lack of impairment of the disease in response to Enzyme Replacement Therapy (ERT).&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A single center observational prospective study.&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      Patients with adult onset POMPE disease (onset of symptoms after two years old) and molecular&#xD;
      diagnosis confirming the disease are eligible&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Clinical information will be obtained according to a pre-defined protocol including six&#xD;
      visits: screening visit, baseline, 6 month, 12 month, 24 month and 36 month.&#xD;
&#xD;
      In each visit we will perform the following tests: clinical assessment (including interview&#xD;
      with patients, quality of live questionnaires, timed tests and assessment of muscle balance&#xD;
      using a myometer), analytical tests (blood and urine tests), cardiac test (Electrocardiogram&#xD;
      (ECG) and cardiac echography), respiratory assessment (using spirometer) and skeletal muscle&#xD;
      imaging (Muscle MRI).&#xD;
&#xD;
      All data collect will be introduced in a database and afterwards statistically analyzed.&#xD;
&#xD;
      Expected results:&#xD;
&#xD;
      We expect to find a biomarker useful to follow-up the progression of Pompe disease. This&#xD;
      biomarker has to be sensitive to the changes that muscle function may have after treatment&#xD;
      with ERT.&#xD;
&#xD;
      Funding:&#xD;
&#xD;
      This project is funded by Genzyme, a Sanofi company&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in muscle atrophy using muscle MRI in patients with adult onset Pompe disease</measure>
    <time_frame>baseline, 6 months, one year, two years and three years</time_frame>
    <description>To know the natural progression of the disease regarding muscle atrophy measured using muscle MRI during a period of three years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>baseline, 6 months, one year, two years and three years</time_frame>
    <description>To study progression of muscle weakness using manual and informatic devices as myometry. We will compare clinical progression with Muscle MRI results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micro RNA study</measure>
    <time_frame>baseline, 6 months, one year, two years and three years</time_frame>
    <description>We will obtain blood samples of all the patients to study the microRNA profile and different time points</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>Pompe patients</arm_group_label>
    <description>Adult onset pompe patients being or not treated with enzyme therapy replacement</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood an urine samples will be obtained&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult onset Pompe Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pompe disease confirmed using genetic study&#xD;
&#xD;
          -  Onset of symptoms more than 2 years old&#xD;
&#xD;
          -  To be able to come to the hospital and follow all the visits&#xD;
&#xD;
          -  Patients with respiratory involvement are welcomed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to perform a MRI (respiratory problems can be solved using mechanical&#xD;
             ventilation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Díaz Manera, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Illa, MD pHD</last_name>
    <role>Study Director</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Díaz_Manera, MD PhD</last_name>
    <phone>0034-935565986</phone>
    <phone_ext>5986</phone_ext>
    <email>JDiazM@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonia Segovia Simon</last_name>
    <phone>0034-935565978</phone>
    <phone_ext>5978</phone_ext>
    <email>SSegovia@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu iSant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Díaz Manera, MD PhD</last_name>
      <phone>0034-935565986</phone>
      <phone_ext>5986</phone_ext>
      <email>JDiazM@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Segovia Simon</last_name>
      <phone>0034-935565978</phone>
      <phone_ext>5978</phone_ext>
      <email>SSegovia@santpau.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi Díaz-Manera, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduard Gallardo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aida Alejaldre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Izaskun Belmonte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POMPE</keyword>
  <keyword>Glycogenosis type II</keyword>
  <keyword>Acid maltase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

